HK1217292A1 - 基於k- ras的突变状态治疗癌症的方法 - Google Patents

基於k- ras的突变状态治疗癌症的方法 Download PDF

Info

Publication number
HK1217292A1
HK1217292A1 HK16105270.2A HK16105270A HK1217292A1 HK 1217292 A1 HK1217292 A1 HK 1217292A1 HK 16105270 A HK16105270 A HK 16105270A HK 1217292 A1 HK1217292 A1 HK 1217292A1
Authority
HK
Hong Kong
Prior art keywords
treating cancer
ras
mutation status
cancer based
status
Prior art date
Application number
HK16105270.2A
Other languages
English (en)
Chinese (zh)
Inventor
Daniel Pierce
Carrie BRACHMANN
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of HK1217292A1 publication Critical patent/HK1217292A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HK16105270.2A 2013-01-11 2014-01-10 基於k- ras的突变状态治疗癌症的方法 HK1217292A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361848793P 2013-01-11 2013-01-11
US61/848793 2013-01-11
US201361752417P 2013-01-14 2013-01-14
US61/752417 2013-01-14
US13/794,712 US20140199405A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on mutation status of k-ras
US13/794712 2013-03-11
PCT/US2014/011097 WO2014110408A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on mutation status of k-ras

Publications (1)

Publication Number Publication Date
HK1217292A1 true HK1217292A1 (zh) 2017-01-06

Family

ID=51165319

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105270.2A HK1217292A1 (zh) 2013-01-11 2014-01-10 基於k- ras的突变状态治疗癌症的方法

Country Status (12)

Country Link
US (1) US20140199405A1 (enExample)
EP (1) EP2943184A4 (enExample)
JP (1) JP2016506908A (enExample)
KR (1) KR20150103746A (enExample)
AU (1) AU2014205254A1 (enExample)
BR (1) BR112015016466A2 (enExample)
CA (1) CA2897581A1 (enExample)
HK (1) HK1217292A1 (enExample)
IL (1) IL239740A0 (enExample)
MX (1) MX2015008889A (enExample)
WO (1) WO2014110408A1 (enExample)
ZA (1) ZA201504878B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
SMT201900502T1 (it) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
BR112016013138A2 (pt) 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos
WO2015169804A1 (en) * 2014-05-06 2015-11-12 Targovax As Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
AU2017340913A1 (en) * 2016-10-07 2019-04-18 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
EP3444272A1 (en) * 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
US20230172935A1 (en) * 2020-05-08 2023-06-08 Cardiff Oncology, Inc. Methods of monitoring kras mutations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
EP1913157B2 (en) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
MX2009009787A (es) * 2007-03-13 2009-09-22 Amgen Inc Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
RU2016119999A (ru) * 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
KR20130043104A (ko) * 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2011146803A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
EP3444363B1 (en) * 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2865335A1 (en) * 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013138371A1 (en) * 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody

Also Published As

Publication number Publication date
IL239740A0 (en) 2015-08-31
JP2016506908A (ja) 2016-03-07
MX2015008889A (es) 2015-11-13
EP2943184A4 (en) 2016-07-20
ZA201504878B (en) 2016-10-26
EP2943184A1 (en) 2015-11-18
CA2897581A1 (en) 2014-07-17
AU2014205254A1 (en) 2015-07-23
WO2014110408A1 (en) 2014-07-17
US20140199405A1 (en) 2014-07-17
KR20150103746A (ko) 2015-09-11
BR112015016466A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
HK1217180A1 (zh) 根據一種核苷轉運載體的水平治療癌症的方法
HK1220405A1 (zh) 治疗膀胱癌的方法
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
MX2015011752A (es) Metodos para tratar cancer de pulmon.
HK1219231A1 (zh) 治疗儿童实体瘤的方法
HK1247092A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
EP3291832A4 (en) Nanoparticle compositions for sustained therapy
PH12016502066A1 (en) Methods of treating bladder cancer
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
HK1220155A1 (zh) 治疗癌症的方法
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
EP3277270A4 (en) Compositions and methods for treating anemia
HK1250944A1 (zh) 用於治疗癌症的方法
HK1245158A1 (zh) 阿吡莫德组合物及其使用方法
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
HK1255835A1 (zh) 用於治疗乙型肝炎的治疗组合物及方法
IL250844A0 (en) Medical nanoparticles and related preparations, methods and systems
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
EP3181137A4 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3